相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy
Nan Cheng et al.
BIOCHEMICAL PHARMACOLOGY (2021)
Silencing of BCSG1 with specific siRNA via nanocarriers for breast cancer treatment
Chenbo Yang et al.
BULLETIN DU CANCER (2021)
Overdiagnosis and Risks of Breast Cancer Screening
Colleen H. Neal et al.
RADIOLOGIC CLINICS OF NORTH AMERICA (2021)
B7-H3 and B7-H4 Expression in Breast Cancer and Their Association with Clinicopathological Variables and T Cell Infiltration
Nah Ihm Kim et al.
PATHOBIOLOGY (2020)
Design, synthesis and biological evaluation of new Myo-inositol derivatives as potential RAS inhibitors
Javeena Hussain et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Gene expression signatures: A tool for analysis of breast cancer prognosis and therapy
Neetha Rajan Latha et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Strategic Developments & Future Perspective on Gene Therapy for Breast Cancer: Role of mTOR and Brk/PTK6 as Molecular Targets
Roja Sahu et al.
CURRENT GENE THERAPY (2020)
Prognostic value of immune checkpoint molecules in breast cancer
Jun Fang et al.
BIOSCIENCE REPORTS (2020)
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer
Juniper A. Scribner et al.
MOLECULAR CANCER THERAPEUTICS (2020)
B7-H3 regulates KIF15-activated ERK1/2 pathway and contributes to radioresistance in colorectal cancer
Yanchao Ma et al.
CELL DEATH & DISEASE (2020)
Inhibition of growth and lung metastasis of breast cancer by tumor-homing triple-bioresponsive nanotherapeutics
Xueqing Zhang et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Molecular mechanisms of breast cancer chemoresistance by immune checkpoints
Narges Dastmalchi et al.
LIFE SCIENCES (2020)
B7-H3-Induced Signaling in Lung Adenocarcinoma Cell Lines with Divergent Epidermal Growth Factor Receptor Mutation Patterns
Meng Ding et al.
BIOMED RESEARCH INTERNATIONAL (2020)
Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors
Meijia Yang et al.
THERANOSTICS (2020)
Breast cancer prognosis signature: linking risk stratification to disease subtypes
Fulong Yu et al.
BRIEFINGS IN BIOINFORMATICS (2019)
Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation
Zixing Liu et al.
ONCOGENE (2019)
Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer
Jangsoon Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma
Rui Cheng et al.
APMIS (2018)
B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients
Monika Pizon et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation
Ying Zhao et al.
ONCOLOGY REPORTS (2017)
Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
Sathana Dushyanthen et al.
NATURE COMMUNICATIONS (2017)
Breast Cancer-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
Armando E. Giuliano et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
MEK2 controls the activation of MKK3/MKK6-p38 axis involved in the MDA-MB-231 breast cancer cell survival: Correlation with cyclin D1 expression
Hugo W. Huth et al.
CELLULAR SIGNALLING (2016)
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
Elodie Picarda et al.
CLINICAL CANCER RESEARCH (2016)
Breast Cancer Detection by B7-H3-Targeted Ultrasound Molecular Imaging
Sunitha V. Bachawal et al.
CANCER RESEARCH (2015)
Expression of B7-H3, a Potential Factor of Tumor Immune Evasion in Combination with the Number of Regulatory T Cells, Affects Against Recurrence-Free Survival in Breast Cancer Patients
N. Maeda et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
PKD1 Phosphorylation-Dependent Degradation of SNAIL by SCF-FBXO11 Regulates Epithelial-Mesenchymal Transition and Metastasis
Hanqiu Zheng et al.
CANCER CELL (2014)
The oncoprotein HBXIP enhances migration of breast cancer cells through increasing filopodia formation involving MEKK2/ERK1/2/Capn4 signaling
Yinghui Li et al.
CANCER LETTERS (2014)
Expression of cell adhesion molecules and prognosis in breast cancer
S. Saadatmand et al.
BRITISH JOURNAL OF SURGERY (2013)
Sox4 Is a Master Regulator of Epithelial-Mesenchymal Transition by Controlling Ezh2 Expression and Epigenetic Reprogramming
Neha Tiwari et al.
CANCER CELL (2013)
Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways
A. Bianchi-Smiraglia et al.
ONCOGENE (2013)
Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems
Teddy S. Nagaria et al.
NEOPLASIA (2013)
Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
Vesselina G. Cooke et al.
CANCER CELL (2012)
EMT as the ultimate survival mechanism of cancer cells
Neha Tiwari et al.
SEMINARS IN CANCER BIOLOGY (2012)
MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes
S. Fujii et al.
ONCOGENE (2011)
B7-H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis
Takaaki Arigami et al.
ANNALS OF SURGERY (2010)
Genetic susceptibility to breast cancer
Nasim Mavaddat et al.
MOLECULAR ONCOLOGY (2010)
Targeting the RAF-MEK-ERK pathway in cancer therapy
Clara Montagut et al.
CANCER LETTERS (2009)
分享论文
